ZDHHC1 and posterior cortical atrophy: By analyzing its relationship with PCa in terms of clinicopathological characteristics, tumor immune microenvironment and response to drug treatment, it was found that this risk model was of good clinical significance.[102] Luo et al constructed a risk prediction model containing 6 PRGs based on a relevant database, and reliability assessment suggested that ZDHHC1 accounted for considerable weighting.